Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that FGFR2::v status confers therapeutic sensitivity to Pemigatinib in patients with Cholangiocarcinoma.
Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
This statement is based on a regulatory approval from the Health Canada:
PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |